NK Cell Characterization
Oncology
Key Facts
About CellChorus
CellChorus is a private, early-stage biotech company founded in 2019 that has developed a unique AI-powered platform for dynamic single-cell functional analysis. Its core technology, TIMING™, visualizes and quantifies the behavior of thousands of individual cells in parallel, providing insights into cell therapy potency, antibody function, and immune response that are missed by conventional bulk or static single-cell methods. The company operates primarily as a technology platform and services provider, supporting pharmaceutical and biotech clients in preclinical research, candidate selection, and manufacturing consistency. CellChorus is positioned to address critical bottlenecks in immunotherapy development by delivering high-content, single-cell kinetic data.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |